title: Interactions of estradiol and NSAIDS on carrageenan-induced hyperalgesia.
abstract: How exogenous estrogen affects inflammatory responses is poorly understood despite the large numbers of women receiving estrogen-alone hormone therapy. The aim of this study was to determine if estradiol alters injury- or inflammation-induced nociceptive responses after carrageenan administration in females and whether its effects are mediated through cyclo-oxygenase (COX) and prostaglandins (PG). To this end, paw withdrawal latencies and serum levels of PGE2 and PGD2 were measured in rats treated with estradiol (0, 10, 20, and 30%) and/or SC560 (COX-1 inhibitor) or NS398 (COX-2 inhibitor) after intraplantar carrageenan administration. Estradiol significantly increased withdrawal latencies before (baseline condition) and after carrageenan administration to one hindpaw. NS398 was anti-nociceptive only in carrageenan treated animals. SC560 increased withdrawal latencies in both paws at 1 and 5hours after carrageenan administration. Co-administration of estradiol and NS398, but not SC560, was additive except for a prolonged anti-nociceptive effects of estradiol combined with NS398. The anti-nociceptive effect extended beyond that observed with either drug or estradiol alone at the 5-hour time point. Estradiol had no significant effect on PGE2 serum levels, but both COX antagonists decreased them. Although neither estradiol nor the COX inhibitors alone had an effect on PGD2 serum levels, co-administration of NS398 and estradiol significantly elevated PGD2 levels. Taken together, our results suggest that estradiol is anti-nociceptive in the thermal test and reduces carrageenan-induced hyperalgesia. These effects are minimally altered through PG-mediated mechanisms.
authors.affiliation: Hunter College and The Graduate Center, The City University of New York, NY, 10065, USA; New York State Psychiatric Institute, New York, NY, 10032, USA.
authors.forename: Deirtra A
authors.initials: DA
authors.lastname: Hunter
authors.forename: Gordon A
authors.initials: GA
authors.lastname: Barr
authors.forename: Kai-Yvonne
authors.initials: KY
authors.lastname: Shivers
authors.forename: Nicole
authors.initials: N
authors.lastname: Amador
authors.forename: Shirzad
authors.initials: S
authors.lastname: Jenab
authors.forename: Charles
authors.initials: C
authors.lastname: Inturrisi
authors.forename: Vanya
authors.initials: V
authors.lastname: Quinones-Jenab
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000378:metabolism / Q000494:pharmacology*; D002351:Carrageenan / Q000037:antagonists & inhibitors; D004195:Disease Models, Animal; D004357:Drug Synergism; D004967:Estrogens / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D006930:Hyperalgesia / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D009619:Nociceptors / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004967:Estrogens; D002351:Carrageenan